Overview

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: - Assess the efficacy of foselutoclax compared to aflibercept - Assess the safety and tolerability of foselutoclax
Phase:
Phase 2
Details
Lead Sponsor:
Unity Biotechnology, Inc.
Treatments:
Aflibercept